Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that Dapagliflozin, as a highly selective SGLT-2 inhibitor,38 may have the ability to influence the function of central autonomic control that results in neural activation related to BP and HR regulation.”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [38]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
The Kidney: Physiology and Pathophysiology
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-544_3 · Cited by 1,673
Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
Saydah, S. H. (2004) · JAMA · doi:10.1001/jama.291.3.335 · Cited by 1,357
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Kanai, Y., Lee, W. S., You, G., Brown, D., & Hediger, M. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116972 · Cited by 630
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Research works printed but not linked: 17
- Washburn W., 2007, 234th National ACS Meeting
- 2006, Diabetes Atlas
- Bertoni A. G., 2007, Diabetes Care
- Mueller G., 2002, Recent Res. Develop. Endocrinol., 3, 199
- Moe O. W., 2000, The Kidney, 375
- Wright E. M., 1993, Soc. Gen. Physiol. Ser., 48, 229
- Wright E. M., 1992, Acta Physiol. Scand., Suppl., 146, 201
- Wells R. G., 1992, Am. J. Physiol., 263, F459
- Santer R., 2000, J. Inher. Metab. Dis., 23, 178
- 2004, Chem. Abstr., 142, 94061
- 2004, Chem. Abstr., 141, 332411
- 2004, Chem. Abstr., 141, 123854
- 2003, Chem. Abstr., 138, 153771
- 2001, Chem. Abstr., 135, 273164
- 2001, Chem. Abstr., 135, 273163
- 2003, Chem. Abstr., 138, 221784
- 2004, Chem. Abstr., 141, 89317
Cited by
Items 401–500 of 684
Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement
Lalhmangaihzuala, S., Vanlaldinpuia, K., Khiangte, V., Laldinpuii, Z., liana, T., Lalhriatpuia, C., & Pachuau, Z. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10810-2 · Cited by 15
“13A), launched by Bristol-Myers Squibb and AstraZeneca in 2012, becomes the first Sodium-glucose co-transporter-2 (SGLT2) inhibitors available for type-2-diabetes mellitus (T2DM) patients [170].”
Recent advances in the synthesis of SGLT2 Inhibitors and natural products from carbohydrates
Tiwari, B., Pandey, R. P., & Hussain, N. (2025) · Carbohydrate Research · doi:10.1016/j.carres.2025.109477 · Cited by 9
TiCl 4 -mediated deoxygenative reduction of aromatic ketones to alkylarenes with ammonia borane
Zang, Y., Ma, Y., Xu, Q., Li, G., Chen, N., Li, X., & Zhu, F. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01977b · Cited by 9
Yano, G., Hyakumura, M., Nakano, K., Yasukouchi, H., Kawachi, H., Funabashi, M., Ohishi, T., Ogawa, Y., & Nishiyama, A. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00385 · Cited by 9
Li, X., Wells, K. M., Branum, S., Damon, S., Youells, S., Beauchamp, D. A., Palmer, D. R. J., Stefanick, S. M., Russell, R. K., & Murray, W. V. (2012) · Organic Process Research & Development · doi:10.1021/op3001355 · Cited by 9
Hamouda, N. N., Qureshi, M. A., Alkaabi, J., Öz, M., & Howarth, F. C. (2016) · Physiological Research · doi:10.33549/physiolres.933045 · Cited by 9
Liang, P., Xu, Q., Chen, R., He, D., Jin, S., Yang, Q. K., & Zhang, J. (2022) · Carbohydrate Research · doi:10.1016/j.carres.2022.108629 · Cited by 9
A facile synthesis of 6-deoxydapagliflozin
Shi, Y., Xu, H., Liu, B., Kong, W., Wei, Q., Xu, W., Tang, L., & Zhao, G. (2013) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-013-1053-0 · Cited by 9
Evidence, illness, and causation: An epidemiological perspective on the Russo–Williamson Thesis
Fiorentino, A. R., & Dammann, O. (2015) · Studies in History and Philosophy of Science Part C Studies in History and Philosophy of Biological and Biomedical Sciences · doi:10.1016/j.shpsc.2015.09.010 · Cited by 13
Washburn, W. N. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00023-7 · Cited by 10
Self-citationSohail, E., Ahsan, T., Ghaus, S., & Aijaz, W. (2020) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.1.2701 · Cited by 13
Stereoselective Synthesis of C-Aryl-α-Glycosides by Reductive C(sp2)–C(sp3) Cross-Coupling Reaction
Kudo, N., Chiba, S., Usui, K., Hirai, G., Ono, S., Nagatoishi, M., Yoritate, M., & Karasawa, S. (2024) · Synlett · doi:10.1055/a-2352-4760 · Cited by 8
Morillas, H., Galcerá, E., Alania-Torres, E., Seller, J., Larumbe, A., Núñez, J. E., & Valle, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2304139 · Cited by 9
“This agent had a longer half-life, high hydrolysis resistance, and a greater affinity for SGLT2 receptors [5].”
Xie, K., Zhang, Y., Chen, R., Chen, D., Yang, L., Liu, X., & Dai, J. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.04.041 · Cited by 8
van der Hoek, S., Antunes, I. F., Attia, K. A., Jacquet, O., Heeres, A., Bulthuis, M. L. C., Zijlma, R., Boersma, H. H., van Goor, H., Visser, T. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01269 · Cited by 8
C‐Aryl Glycosylation via Interrupted Pummerer Rearrangement†
Li, J., & Jiang, X. (2023) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202300308 · Cited by 8
Braem, A. D., Deshpande, P. P., Ellsworth, B. A., & Washburn, W. N. (2014) · Topics in medicinal chemistry · doi:10.1007/7355_2014_41 · Cited by 8
Self-citationConvenient Access to 2‐β‐ d ‐Glucopyranosylpyridines by Using Bohlmann–Rahtz Heteroannulation
Reddy, M. R., & Aidhen, I. S. (2018) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201800789 · Cited by 8
Sodium–Glucose Cotransporter-2 Inhibitors: Lack of a Complete History Delays Diagnosis
Leslie, B. R., Gerwin, L. E., & Taylor, S. I. (2019) · Annals of Internal Medicine · doi:10.7326/m19-1463 · Cited by 9
Xu, L., Hou, Z., Xian, M., Ma, Y., Wang, J., Zhang, X., Wang, P., & Li, M. (2022) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.202100665 · Cited by 7
Xin, Y., Zhou, S., Wang, H., Hu, B., Zhang, Z., Wang, J., & Sun, T. (2021) · New Journal of Chemistry · doi:10.1039/d1nj02510d · Cited by 7
Butler, M. S. (2009) · Royal Society of Chemistry eBooks · doi:10.1039/9781847559890-00321 · Cited by 7
Zhang, S., Wang, Y.-L., Wei, Q., Xu, W., Li-da, T., Zhao, G., & Wang, J. (2013) · Chinese Chemical Letters · doi:10.1016/j.cclet.2013.03.026 · Cited by 7
Ponnapalli, K. K., Adak, A. K., Das, A., Song, J., Wu, S.-H., Sun, C., & Lin, C. (2017) · Asian Journal of Organic Chemistry · doi:10.1002/ajoc.201700148 · Cited by 7
Sirois, L. E., Zhao, M. M., Lim, N., Bednarz, M. S., Harrison, B. A., & Wu, W. (2018) · Organic Process Research & Development · doi:10.1021/acs.oprd.8b00325 · Cited by 7
Zhou, X., Ding, H., Chen, P., Liu, L., Sun, Q., Wang, X., Wang, P., Lv, Z., & Li, M. (2019) · Angewandte Chemie · doi:10.1002/ange.201914557 · Cited by 7
Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD
Kula, A. J. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05456-x · Cited by 7
“Most SGLT2is do demonstrate cross-reactivity with SGLT1, but the relative effect is trivial and clinically insignificant [13].”
BackgroundAi, Y., Zhang, Y., Chen, W., Zhou, X., Dong, Y., Yang, Q., & Zhang, J. (2025) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2025.106737 · Cited by 6
Ramírez-Mulhern, I., Navarro-Sánchez, V., Rivero-Otamendi, E., Sánchez-Mejía, D. E., Zavala-Miranda, M. F., & Mejia-Vilet, J. M. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf548 · Cited by 6
Glycosyl Radical-Based C–H Glycosylation of Coumarins Enabled by Photocatalysis
Pan, Q., Wang, M., Tu, Y., Rui, P., & Hu, X. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c04327 · Cited by 6
Zhao, X., Ning, R., Hui, A., Boulton, D. W., & Tang, W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.012 · Cited by 6
Wang, L., Xi, W., Yuan, X.-L., & Yang, X.-H. (2023) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c22-00843 · Cited by 6
Wang, W., Wu, J., Jiang, K.-Y., Zhou, M., & He, G. (2024) · Chemical Science · doi:10.1039/d4sc07410f · Cited by 6
Switchable and Stereospecific C- Glycosylation Strategy via Formal Functional Group Deletion
Ma, X., & Sujansky, S. J. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c00200 · Cited by 6
Synthesis of complex oxygenated heterocycles
Nicolas, L., Butkevich, A. N., Guérinot, A., Corbu, A., Reymond, S., & Cossy, J. (2013) · Pure and Applied Chemistry · doi:10.1351/pac-con-12-09-15 · Cited by 6
OLIVEROS, R. A., Pham, S. V., Bailey, S. R., & CHILTON, R. J. (2014) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2014.10.02.117 · Cited by 6
Cada, D. J., Levien, T. L., & Baker, D. E. (2014) · Hospital Pharmacy · doi:10.1310/hpj4907-647 · Cited by 9
Synthetic Approaches to Gliflozins: A Comprehensive Overview
Nahide, P. D., Ratnamala, A., Bandichhor, R., Sasikala, C. V. A., Beesu, M., Biswas, S., Basu, D., & Achanta, S. (2024) · Synthesis · doi:10.1055/s-0042-1751524 · Cited by 6
Šaler, F., Viđak, M., & Puljak, L. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02292-5 · Cited by 6
“First developed SGLT2 inhibitor was dapagliflozin [31], followed by empagliflozin and canagliflozin.”
BackgroundChoi, J. B., Yoo, J. M., Lee, Y., Kim, J. W., Lee, S., Kim, H. Y., Lee, D. S., Ko, S., & Choe, H. (2020) · International Neurourology Journal · doi:10.5213/inj.1938220.110 · Cited by 6
“Among them, dapagliflozin is a highly selective inhibitor of SGLT2 [10], and many clinical studies have reported its efficacy and safety in patients with T2DM as monotherapy or combination therapy [11].”
BackgroundKuhre, R. E., Deacon, C. F., Albrechtsen, N. J. W., & Holst, J. J. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14422 · Cited by 8
Somsák, L., Bokor, É., Czifrák, K., Juhász, L., & Tóth, M. (2011) · InTech eBooks · doi:10.5772/23463 · Cited by 6
Singh, M. K., & Lakshman, M. K. (2015) · ChemCatChem · doi:10.1002/cctc.201500818 · Cited by 6
LaCreta, F. P., Griffen, S. C., Liu, X., Smith, C. H., Hines, C., Volk, K., Tejwani, R. W., & Boulton, D. W. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.07.017 · Cited by 6
Prybyla, О. В. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.4.2021.237342 · Cited by 6
Dapagliflozin: where does it fit in the treatment of type 2 diabetes?
Woo, V. C. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903222281 · Cited by 6
“1 mg/kg reduced fasting glucose levels from 17 to 55% [34].”
BackgroundA novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors
Niazi, A. K., & Niazi, S. H. (2010) · North American Journal of Medical Sciences · doi:10.4297/najms.2010.2556 · Cited by 6
Stereoselective Conversion of Sugar Derivatives into C-nucleosides
Miguélez, J., Batchu, V. R., & Boto, A. (2012) · The Journal of Organic Chemistry · doi:10.1021/jo301031t · Cited by 6
Glucose Reabsorption in The Kidney
Hummel, C. S., & Wright, E. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381462-3.00070-7 · Cited by 6
Finding New Molecular Targets of Familiar Natural Products Using In Silico Target PredictionPreprint
Mayr, F., Möller, G., Garscha, U., Fischer, J., Castaño, P. R., Inderbinen, S. G., Temml, V., Waltenberger, B., Schwaiger, S., Hartmann, R. W., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.01.181859 · Cited by 6
Multi‐target Drugs to Treat Metabolic Diseases
Lillich, F. F., Goorani, S., Proschak, E., & Imig, J. D. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch13 · Cited by 6
Zhang, Z., Li, Y., Gu, H. F., & Li, N. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118837 · Cited by 5
Dey, A. K., Groenendyk, J., Mehta, N. N., & Gourgari, E. (2019) · Clinical Cardiology · doi:10.1002/clc.23152 · Cited by 5
Soares, R. R., Viggiani, L. F., Filho, J. M. R., & Joviano‐Santos, J. V. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111229 · Cited by 5
Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions
Sodini, S., & Suárez‐Ortegón, M. F. (2025) · Diabetology · doi:10.3390/diabetology6060048 · Cited by 6
“Ongoing clinical studies are exploring associations between SGLT2 inhibitor use and cellular senescence in patients with type 2 diabetes [112].”
Structural Perspectives and Advancement of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes
Sharma, S., Mittal, A., Kumar, S., & Mittal, A. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210917122745 · Cited by 5
Vertical Sleeve Gastrectomy Lowers SGLT2/ Slc5a2 Expression in the Mouse Kidney
Akalestou, E., López–Noriega, L., Tough, I. R., Hu, M., Leclerc, I., Cox, H. M., & Rutter, G. A. (2022) · Diabetes · doi:10.2337/db21-0768 · Cited by 5
The Emerging Promise with O/C‐Glycosides of Important Dietary Phenolic Compounds
Aidhen, I. S., Srikanth, S., & Lal, H. B. (2022) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202200758 · Cited by 5
Chen, H., Sahu, S. K., Wang, S., Liu, J., Yang, J., Cheng, L., Chiu, T., & Liu, H. (2024) · iScience · doi:10.1016/j.isci.2024.109599 · Cited by 6
Zhao, W. J., Shi, Y. H., Zhao, G., Wang, Y. L., Shao, H., Tang, L. D., & Wang, J. (2011) · Chinese Chemical Letters · doi:10.1016/j.cclet.2011.05.022 · Cited by 5
Pharmacotherapy for obesity: a field in crisis?
Fenske, W., Parker, J. A., & Bloom, S. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 4
Dapagliflozina: Más allá del control glucémico en el tratamiento de la diabetes mellitus tipo 2
Sanz-Serra, P., Pedro‐Botet, J., Roux, J. A. F., Benaiges, D., & Chillarón, J. J. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.11.001 · Cited by 8
Jiang, M., & Steyger, P. S. (2015) · PubMed · doi:10.1517/13543776.2015.1076392 · Cited by 5
“Susceptibility to glucosidase degradation was overcome by the discovery of C-glycosides such as dapagliflozin [6,7] and canagliflozin [8,9], with increased lipophilicity and molecular weight [18].”
BackgroundLemaire, S., & Schils, D. (2015) · Topics in heterocyclic chemistry · doi:10.1007/7081_2015_166 · Cited by 5
Tejedor, A. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(17)30624-3 · Cited by 8
In silico modeling and in vitro activity of vitexin and isovitexin against SGLT2
Shi, Y., Meng, F., Liu, J., & Wang, B. (2019) · Journal of Theoretical and Computational Chemistry · doi:10.1142/s0219633619500354 · Cited by 5
Bahriz, A., Ismaiel, Y., Abdelhameed, A. A., & Elsayed, F. (2021) · Benha Medical Journal · doi:10.21608/bmfj.2021.146796 · Cited by 5
Efficient Route to Canagliflozin via Anhydroketopyranose
Sasikala, C. V. A., Ratnamala, A., Basu, D., Singarapu, K. K., Mohammad, A., & Bandichhor, R. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c00980 · Cited by 5
Cada, D. J., Ingram, K. T., Levien, T. L., & Baker, D. E. (2013) · Hospital Pharmacy · doi:10.1310/hpj4810-855 · Cited by 5
“Approximately 90% of renal glucose reabsorption is facilitated by SGLT2 in the S1 segment of the proximal tubule, and the other 10% is facilitated by SGLT1 in the distal S3 segment of the proximal tubule.(1,2,6) Canagliflozin lowers plasma glucose in a dosedependent manner by lowering the renal threshold for glucose a…”
SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
Theofilis, P., & Kalaitzidis, R. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221227091943 · Cited by 6
Xie, T., & Zhao, L.-J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116343 · Cited by 7
Therapeutic Treatment for Controlling Childhood Obesity
Hossain, M. A., Pervin, R., Debnath, D., & Bhuiyan, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812840-4.00030-x · Cited by 6
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
Singh, S., & Gupta, A. K. (2014) · Muller Journal of Medical Sciences and Research · doi:10.4103/0975-9727.135761 · Cited by 5
Belew, Z. M., Crocoll, C., Møller‐Hansen, I., Næsby, M., Borodina, I., & Nour‐Eldin, H. H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.14.248047 · Cited by 5
“…levels, has been used as both a remedy and a tool to study renal physiology for nearly two centuries and has been used as a blueprint to develop several commercialized anti-diabetic drugs (Ehrenkranz et al., 2005; Kramer and Zinman, 2019; Meng et al., 2008; Nomura et al., 2010; Scheen, 2015).”
MethodZeng, H. D., Ouyang, W., Liu, S., Wang, J., Rui, P., & Hu, X. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202502233 · Cited by 4
Parveen, A., Parveen, S., Vats, N., Shafeeque, M., Choudhary, A., Zaidi, S. A. H., & Yar, M. S. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70127 · Cited by 4
Gama, F. D. S., Ferreira, M. A., Segretti, N., Damião, M. C. F. C. B., Guimarães, C. R. W., Mascarello, A., & de Azevedo, H. F. Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02225 · Cited by 4
Jin, B., Kumari, T., Lee, J., Kim, J.-S., Bokorová, R., Gheware, A., Ripoll, C. V., Sargazi, A., Jeong, S., Hyun, Y., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag003 · Cited by 4
Bueno, L. M., Manoel, J. W., Koetz, M., Henriques, A. T., Steppe, M., Piton, Y. V., Arbo, M., Garcia, S. C., & Schapoval, E. E. S. (2023) · Drug Analytical Research · doi:10.22456/2527-2616.128661 · Cited by 4
Structure-property Relationships Reported for the New Drugs Approved in 2022
Choi, K. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230519162803 · Cited by 5
Tiwari, R. K., Ahmad, A., Chadha, M., Saha, K., Verma, H., Borgohain, K., & Shukla, R. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998294919240506044544 · Cited by 5
Total Syntheses of Deuterated Drugs: A Comprehensive Review
Munir, R., Zahoor, A. F., Khan, S. G., Hussain, S. M., Noreen, R., Mansha, A., Hafeez, F., Irfan, A., & Ahmad, M. H. (2025) · Topics in Current Chemistry · doi:10.1007/s41061-025-00515-x · Cited by 6
Dapagliflozin for the treatment of Type 2 diabetes
Woo, V. C., & Ho, J. D. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.950226 · Cited by 4
“The two major glucose transporters are SGLT-1 and SGLT-2 [15,16].”
BackgroundInfluentialSynthesis of metabolites of dapagliflozin: an SGLT2 inhibitor
Karumanchi, K., Natarajan, S. K., Chavakula, R., Korupolu, R. B., BONIGE, K. B., & Gupta, P. B. (2020) · Journal of Chemical Sciences · doi:10.1007/s12039-020-1747-x · Cited by 4
Pyranoid Spirosugars as Enzyme Inhibitors
Ferla, B. L., & D’Orazio, G. (2020) · Current Organic Synthesis · doi:10.2174/1570179417666200924152648 · Cited by 4
Gandhi, A., Masand, V. H., Zaki, M. E. A., Al‐Hussain, S. A., Ghorbal, A. B., & Chapolikar, A. (2021) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2021.1971295 · Cited by 4
The Role of the Kidney in Glucose Homeostasis
Mota, M., Moța, E., & Dinu, R. (2015) · InTech eBooks · doi:10.5772/59173 · Cited by 5
“Ellsworth et al [46] discovered a group of C-aryl glycosides that includes dapagliflozin [47] and canagliflozin [48].”
BackgroundKifayatullah, M., Mustapha, M., Sarker, M. M. R., Kaleemullah, Amin, M., & Ali, F. (2017) · Egyptian Pharmaceutical Journal · doi:10.4103/1687-4315.205824 · Cited by 4
Distale C−H‐Glykosylierung durch Ruthenium(II)‐Katalyse: Modularer Aufbau vonmeta‐C‐Aryl‐Glykosiden
Wu, J., Kaplaneris, N., Pöhlmann, J., Michiyuki, T., Yuan, B., & Ackermann, L. (2022) · Angewandte Chemie · doi:10.1002/ange.202208620 · Cited by 4
Kalra, S., & Bhattacharya, S. (2022) · Journal of Diabetology · doi:10.4103/jod.jod_129_21 · Cited by 4
Bonnet, F., & Sauvanet, J.-P. (2009) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(09)72401-0 · Cited by 4
Cada, D. J., Cong, J., & Baker, D. E. (2015) · Cited by 4
Auld, D., Simeonov, A. M., Lea, W., & Thomas, C. J. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0805.lr · Cited by 4
Diabetes Drugs: Present and Emerging
Tilley, J., Grimsby, J. S., Erickson, S. D., & Berthel, S. J. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc198 · Cited by 4
Ahmed, D., Sharma, M., Kumar, V., & Yadav, P. S. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000358 · Cited by 4
“Though it is a nonselective SGLT inhibitor [16-18].”
BackgroundFinding New Molecular Targets of Familiar Natural Products Using In Silico Target PredictionPreprint
Mayr, F., Möller, G., Garscha, U., Fischer, J., Castaño, P. R., Inderbinen, S. G., Temml, V., Waltenberger, B., Schwaiger, S., Hartmann, R. W., et al. (2020) · Preprints.org · doi:10.20944/preprints202007.0495.v1 · Cited by 4
Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events
de Matos, A. M., Calado, P., Washburn, W. N., & Rauter, A. P. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch4 · Cited by 4
Self-citationCurrent Approaches to Food Waste Valorization for Nutraceuticals
Vu, N. (2025) · Springer eBooks · doi:10.1007/978-981-97-9707-3_12 · Cited by 3
Sharma, S., Kumar, S., Gupta, J., Mittal, A., & Khurana, N. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2463869 · Cited by 5
Photoredox-Catalyzed C-Glycosylation Reactions
Li, C., Jiao, Y., Shi, X., Yang, Y., & Yu, S. (2025) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202408003 · Cited by 3
Metadata
- Authors
- Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., Zahler, R., Deshpande, P. P., Pullockaran, A., Hagan, D. L., Morgan, N., Taylor, J. R., Obermeier, M. T., Humphreys, W. G., Khanna, A., Discenza, L., Robertson, J. G., Wang, A., Han, S., Wetterau, J. R., Janovitz, E. B., Flint, O. P., Whaley, J. M., & Washburn, W. N.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Metabolic Diseases Chemistry, Process R & D, Metabolic Diseases Biology, Pharmacological Candidate Optimization, Drug Safety Evaluation, Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543
- Corresponding author
- Meng, Wei
- Washburn, William N.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-02-09
- Volume
- 51
- Issue
- 5
- Pages
- 1145-1149
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2026609170
- Cited by
- 634
- References
- 39
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 28 · 2023: 23 · 2022: 35 · 2021: 32 · 2020: 40 · 2019: 34 · 2018: 26 · 2017: 22 · 2016: 35 · 2015: 44 · 2014: 40 · 2013: 36 · 2012: 43
- FWCI
- 35.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, antidiabetic drug discovery, blood glucose reduction, streptozotocin-induced hyperglycemia, ADME properties
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Animals, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Glucosides, Humans, Hypoglycemic Agents, Kidney, Stereoisomerism, Sodium-Glucose Transporter 2, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.